Nexalin Technology, Inc. is excited to announce an upcoming webinar that will provide valuable insight into its innovative neurostimulation products. The webinar, hosted by RedChip Companies, will take place on May 23, 2024, at 4:15 p.m. ET and will feature Nexalin CEO Mark White as the keynote speaker.
During the webinar, Mark White will share groundbreaking clinical data that supports Nexalin’s non-invasive, frequency-based deep brain stimulation device. This device has shown promising results in providing relief to individuals suffering from mental health issues. Additionally, White will discuss the progress made on the development of the new Gen-3 HALO™ Clarity & Virtual Clinic model, which aims to further enhance the treatment options available to patients.
Participants of the webinar will have the opportunity to engage in a live Q&A session with Mark White, allowing them to gain further insights and ask specific questions related to Nexalin’s neurostimulation products. To register for the free webinar, individuals can visit the following link: [insert registration link].
In its mission to combat the global mental health epidemic, Nexalin utilizes bioelectronic medical technology to provide effective and non-invasive treatments. The company’s neurostimulation devices are designed to penetrate deep structures in the mid-brain associated with mental health disorders, generating enhanced patient responses without adverse side effects.
Nexalin has received recent approval for its Gen-2 15 milliamp neurostimulation device in Oman and China, indicating the growing recognition and acceptance of its innovative products in the international market.
Please note that any statements regarding Nexalin’s future events or financial performance should be considered forward-looking statements and are subject to various risks and uncertainties. The company remains committed to providing updates and advancements in its neurostimulation products while adhering to regulatory guidelines.
For more information about Nexalin Technology, Inc. and its revolutionary products, please visit their official website: [insert website link].
Press Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
[email protected]
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: [email protected]
Nexalin Technology, Inc. is set to host an informative webinar to share insights into its innovative neurostimulation products. The webinar, scheduled for May 23, 2024, at 4:15 p.m. ET, will be led by Nexalin CEO Mark White. The company’s neurostimulation devices have shown promising results in providing relief to individuals suffering from mental health issues.
One key advantage of Nexalin’s neurostimulation devices is that they are non-invasive and frequency-based. This means that patients can receive treatment without the need for invasive procedures, reducing associated risks and recovery times. Additionally, the devices are specifically designed to target deep structures in the mid-brain associated with mental health disorders, resulting in enhanced patient responses.
During the webinar, Mark White will also discuss the progress made on the development of the new Gen-3 HALO™ Clarity & Virtual Clinic model. This model aims to further enhance the treatment options available to patients, potentially expanding the reach and effectiveness of neurostimulation therapies.
Nexalin has received recent approvals for its Gen-2 15 milliamp neurostimulation device in Oman and China, indicating growing recognition and acceptance of the company’s innovative products in the international market. This suggests that there is a global demand for non-invasive neurostimulation treatments, and Nexalin is positioned to capitalize on this market opportunity.
However, it is important to note that any statements regarding Nexalin’s future events or financial performance should be considered forward-looking statements and are subject to various risks and uncertainties. As with any medical device, regulatory guidelines must be followed to ensure the safety and efficacy of Nexalin’s neurostimulation products.
Moving forward, Nexalin remains committed to providing updates and advancements in its neurostimulation products. By leveraging bioelectronic medical technology, the company aims to combat the global mental health epidemic and offer effective treatment options for individuals in need.
For more information about Nexalin Technology, Inc. and its revolutionary products, individuals can visit their official website: link name.
References:
– Nexalin Technology, Inc. Official Website: link name